Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

Butts, C; Socinski, M; Mitchell, Pa; Thatcher, Nick; Havel, L; Krzakowski, M; Nawrocki, S; Ciuleanu, T; Bosquée, L; Trigo, J; Spira, A; Tremblay, L; Nyman, J; Ramlau, R; Wickart-Johansson, G; Ellis, P; Gladkov, O; Pereira, J; Eberhardt, W; Helwig, C; Schröder, A; Shepherd, F

Affiliation

Cross Cancer Institute, Edmonton, AB, Canada

Issue Date

2014-01

Metadata

Show full item record

Abstract

Effective maintenance therapies after chemoradiotherapy for lung cancer are lacking. Our aim was to investigate whether the MUC1 antigen-specific cancer immunotherapy tecemotide improves survival in patients with stage III unresectable non-small-cell lung cancer when given as maintenance therapy after chemoradiation.

Citation

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. 2014, 15 (1):59-68 Lancet Oncol

Journal

The Lancet Oncology

URI

http://hdl.handle.net/10541/312424

DOI

10.1016/S1470-2045(13)70510-2

PubMed ID

24331154

Type

Article

Language

ISSN

1474-5488

Collections

All Christie Publications